Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor
Purpose Vortioxetine an anti-depressant FDA-drug recently reported showing better in vitro efficacy against SARS-CoV-2. Methods In this study, we have synthesized ten new derivatives having alkenes, alkynes, benzyl, aryl, and mixed carbamate at the N-terminal of vortioxetine. Then the binding energy...
Gespeichert in:
Veröffentlicht in: | Daru 2022-06, Vol.30 (1), p.139-152 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
Vortioxetine an anti-depressant FDA-drug recently reported showing better in vitro efficacy against SARS-CoV-2.
Methods
In this study, we have synthesized ten new derivatives having alkenes, alkynes, benzyl, aryl, and mixed carbamate at the N-terminal of vortioxetine. Then the binding energy and interactions with the crucial amino acid residues in the binding pocket of main protease (M
pro
) of SARS-CoV-2, of reported and ten newly synthesized vortioxetine derivatives (total thirty-one) in comparison with remdesivir are analyzed and presented in this paper.
Results
Based on the docking scores predicted by ADV and AD, most vortioxetine derivatives showed better binding efficiency towards M
pro
of SARS-CoV-2 in comparison with remdesivir (an EUA approved drug against SARS-CoV-2 M
pro
) and vortioxetine.
Conclusion
This study shows that some vortioxetine derivatives can be developed into promising drugs for COVID-19 treatment. |
---|---|
ISSN: | 2008-2231 1560-8115 2008-2231 |
DOI: | 10.1007/s40199-022-00441-z |